Slide 1: First nine months results
2020 First nine months results CONFERENCE CALL – 29 OCTOBER 2020
Slide 2: First nine months 2020 highlights
First nine months 2020 highlights • Resilient performance across the Group despite challenging environment, with Net Revenue of € 1,093.8 million or ‐ 0.6% continuing to reflect COVID‐19 impact on market and significant FX headwind of ‐1.7% YTD (‐3.9% in Q3) • First nine months profitability remains
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 68.9% of revenue (million Euro) 9 mos 2020 9 mos 2019 Change % Zanidip® (lercanidipine) 106.1 102.2 3.8 Zanipress® (lercanidipine+enalapril) 38.2 44.4 (13.8) Urorec® (silodosin) 58.5 82.7 (29.3) Livazo® (pitavastatin
Slide 4: A diversified product portfolio
A diversified product portfolio Other corporate products 11.0% (excluding OTC) Drugs for rare diseases 21.2% Seloken®/Logimax® 7.1% Livazo® 3.9% Urorec® 5.3% Zanipress® 3.5% OTC 18.2% Zanidip® 9.7% Pharmaceutical chemicals 3.5% Subsidiaries’ local product Other revenue 0.7% portfolios 15.9% Data: Fi
Slide 5: Composition of revenue by geography
Composition of revenue by geography (million Euro) 9 mos 2020 9 mos 2019 Change % Italy 202.9 215.1 (5.7) France 109.1 117.0 (6.7) Germany 100.6 101.5 (0.9) U.S.A. 89.4 78.3 14.1 Russia, other CIS countries and Ukraine 69.1 83.6 (17.3) Spain 63.1 69.4 (9.1) Turkey 62.4 65.3 (4.4) Portugal 32.6 33.0
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical* revenue Other international sales 15.1% (sales to licensees, exports, sales in ROW) Italy 19.2% North Africa 3.2% Other W. Europe 6.3% France 10.3% Other CEE 6.4% Portugal 3.1% Germany 9.5% Turkey 5.9% Spain 6.0% Russia, other CIS and U.S.A. 8.5% Ukraine 6.5
Slide 7: First nine months 2020 results
First nine months 2020 results (million Euro) 9 mos 2020 9 mos 2019 Change % Revenue 1,093.8 1,100.4 (0.6) Gross Profit 785.6 771.3 1.8 as % of revenue 71.8 70.1 SG&A Expenses 310.3 325.2 (4.6) as % of revenue 28.4 29.5 R&D Expenses 106.3 91.6 16.1 as % of revenue 9.7 8.3 Other Income (Expense), net
Slide 8: First nine months results by operating segment
First half nine months results Operating Segments EBIT Treatments for rare diseases 26.5% Revenue Treatments for rare diseases 21.2% Specialty & primary care 73.5% EBITDA Treatments for rare diseases 26.7% Specialty & primary care 78.8% Margin on sales: Specialty & primary Treatments for rare diseas
Slide 9: Net financial position
Net financial position 30 Sep 2020 31 Dec 2019 Change (million Euro) Cash and short‐term financial investments 277.6 187.9 89.7 Bank overdrafts and short‐term loans (14.7) (13.4) (1.3) Loans and leases – due within one year* (219.9) (149.8) (70.1) Loans and leases – due after one year* (888.9) (927.
Slide 10: Full year 2020 outlook
Full year 2020 outlook Still expect EBITDA and Adjusted Net Income near lower end of 2020 guidance range despite increased FX and COVID‐19 headwinds • Expect full year revenue marginally below prior year, due to: • Second wave of COVID‐19 lock downs continuing to impact demand also into Q4 • Strong
Slide 11: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Luigi La Corte declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Fina